Mesa Laboratories Q4 2024 GAAP EPS $(47.20) May Not Be Comparable To $(0.12) Estimate, Sales $58.904M Beat $55.275M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mesa Laboratories reported Q4 2024 GAAP EPS of $(47.20), which is not comparable to the $(0.12) estimate. However, the company's sales of $58.904 million beat the $55.275 million estimate.
June 05, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mesa Laboratories reported a significant GAAP EPS loss of $(47.20) for Q4 2024, which is not comparable to the $(0.12) estimate. Despite this, the company exceeded sales expectations with $58.904 million, beating the $55.275 million estimate.
The significant GAAP EPS loss may raise concerns among investors, but the better-than-expected sales could mitigate some negative sentiment. The mixed results are likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100